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Abstract
Conceived with the aim of meeting the needs of the neuro-
biology and clinical communities, the Brain Research
through Advancing Innovative Technologies (BRAIN)
Initiative builds on the lessons learned from major projects
in genetics, such as the Human Genome Project. It concen-
trates on the use of new imaging technologies in conjunc-
tion with genomics to inform therapeutic decisions.   
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The BRAIN Initiative
At the September 2011 meeting on “Opportunities at the
Interface of Neuroscience and Nanoscience,” at the Kavli
Royal Society International Centre, UK, six of the atten-
dees proposed an idea. Within days this became a white
paper at the US Office of Science and Technology Policy,
and then gained momentum among government granting
agencies and private foundations, such that by April 2013
its creation was announced by the US president, complete
with acronym: “Brain Research through Advancing
Innovative Neurotechnologies” (BRAIN). For many pro-
ponents and critics alike, this acronym was a very positive
nuance. It indicated that this project would not be a crank-
turning, dollar-burning, unstoppable juggernaut locked
into 2013 technologies, but rather a dynamic, cost-saving
project, responsive to the real needs of the basic neurobi-
ology and clinical communities. The goal of that project is
aligned with the theme of this journal issue—creative
imaging technologies employed to guide therapies.
Lessons from the Genome Project(s)
Due to the scarcity of examples of either type of project
caricatured above (production or technology), we scruti-
nize the few that exist for analogies and insights to
enhance the best and avoid the worst. 
Lesson one: aggressively encourage technology develop-
ment from the start. There was not a single Genome
Project, but three fundamentally different strategies and
phases—a technology-assessment phase initiated by the
Department of Energy (1984-1990), the NIH-driven pro-
duction phase (Human Genome Project, HGP, 1990-
2004), and the NIH Advanced Sequencing Technology
Development (ASTD, 2004-2013) phase. The BRAIN
project will hopefully focus on the ASTD precedent,
which (with annual funds only 6% of the HGP) helped
drop the cost of sequencing by a million-fold in 6 years.
It achieved this via advanced imaging and highly multi-
plexed biochemistry, not mere parallelism via conven-
tional lab robotics. 
Lesson two: Consider practical applications from the
start. It could be said that brain technologies seem less
mature than genomics at the corresponding project start
points. In reality, no commercial or clinical applications
of genomics existed in 1984. In contrast, at the start of the
BRAIN project, millions of patients already benefit from
cochlear, cardiac, retinal, and deep-brain electrode
implant therapies as well as EEG and imaging technolo-
gies. 
Lesson three: The goal need not be “simple.” While it may
seem that the HGP was digital and one-dimensional, the
deliverable was not raw data of three billion letters (A, C,
G, T). Instead our goal was an “annotated” genome,
including the locations of regulatory elements and
descriptions of the impact of mutations and epigenomics
on developmental biology, disease, and aging. From this
perspective, the BRAIN project is not harder than the
genome project—indeed, it is an unfinished subset. 
Lesson four: Lack of prior “understanding” should not
impede innovation. Vaccines were amazing well before
we understood the immune system. Did we know “THE
genetic code” before HGP? That code only applied to
1% of the genome (the part encoding proteins) and, even
there, did not reveal function. 
The role of innovative imaging technologies
We can leverage exponentially advancing technologies
(optical, electronic, imaging, nanotechnology, and syn-
thetic biology) to radically improve the accuracy, cost,
241and comprehensiveness of neurotechnologies capable of
measurement and alteration of brain development and
functioning in animal models and clinical settings.
Especially valuable would be applying and integrating a
variety of such methods in a single (“Rosetta”) brain
sample. This would include an initial behavioral phase
including MRI, ultrasound, and electrical/optical stimu-
lation/recording, followed by a serial section phase
exploiting fluorescent in situ sequencing (FISSEQ) to
assess RNA transcriptomes, barcoded connectomes, and
time series data (ranging from developmental lineage to
biochemical changes in cell membranes and nuclei). The
physical limits and work-arounds for a variety of imaging
modalities and means of transducing the data on poten-
tial neurons in a brain to an external device have been
recently reviewed.
1
Magnetic resonance imaging
The NIH Human Connectome Project (HCP, 2009-
2014) is ongoing at Washington University, University
of Minnesota, Harvard University, Massachusetts
General Hospital, and UCLA. HCP is largely focused
on imaging methods, which include structural magnetic
resonance imaging (MRI), diffusion tensor imaging
(DTI), high-angular-resolution diffusion imaging
(HARDI), functional MRI (fMRI), and diffusion spec-
trum imaging (DSI). To connect imaging to behavior,
the HCP includes the NIH Toolbox for Assessment of
Neurological and Behavioral function. The highest prac-
tical field gradients, so far, 300 mT/m (with slewing at
200 T/m/s), has resulted in temporal and spatial resolu-
tions of 0.62 msec and 1.5 mm respectively. (One mm
3
contains roughly 50 000 neurons). Some of the above
limits are set by unwanted peripheral nervous system
and retinal stimulation.
2 Proton MRI is limited to 100 ms
temporal resolution by water T1 relaxation time, and
limited to spatial resolutions of 40 µm by the self-diffu-
sion of water. T1 premapping could allow T2 contrast
on a 10-msec timescale.
1
Extracellular electrical recording
Since the maximum recording distance is about 100 µm
to 200 µm measured from electrode to neuron, at current
noise levels, 100 000 minimum in theory and 10 million
electrodes in practice would be required to enable sorting
of noisy, temporally overlapping spikes using current
algorithms. Current arrays are in the hundreds of elec-
trodes, and keeping total volume of the multielectrode
below 1% of the brain volume is challenging.
Alternatively, wireless data transmission or implanted
recording are options. Wireless data transmission at opti-
cal and infrared (IR) frequencies are needed to obtain
adequate single-channel data rates. Radio-frequency
(RF) transmission of whole-brain data would draw exces-
sive power due to bandwidth constraints. Multiplexing
RF wavelengths is likely inadequate, but optical/IR or
ultrasound allow frequency and spatial multiplexing.
Implanted electrical recording would require a 1000-fold
increase in the power efficiency of electronics relative to
current devices to scale to whole-brain simultaneous
recordings. 
Optical imaging
Light scattering imposes significant limits on optical tech-
niques, but strategies exist which could negate the effects
of scattering, such as implantable optics, infrared fluores-
cence or bioluminescence, and online inversion of the
scattering matrix. In larval zebrafish, a calcium indicator
(GCaMP5G) in vivo captured, at 0.8 Hz, 80% of all of
the 100 000 neurons of the whole brain at single-cell res-
olution
3 but scaling this to thicker, less transparent brains
is quite challenging. Whole-brain multi-photon excitation
could overheat the brain, except in very short experi-
ments, unless ultrabright inorganic indicators or similar
strategies can be developed.
4 For beam scanning micro-
scopies, optical phase modulators, in principle, could
reposition beams at 1-GHz switching rates with fluores-
cence lifetimes in the 0.1–1.0 ns range constrain and
enable design of ultrafast scanning.
Ultrasound 
Ultrasound is attenuated by brain tissue at the 100-MHz
frequencies needed for single-cell resolution ultrasound
imaging such that it is hard to detect even in theory.
Nevertheless, ultrasound may be a viable medium for
spatially multiplexed data transmission from embedded
devices.
3
Molecular recording devices
These fall within reasonable physical limits, but their devel-
opment represents major challenges in synthetic biology.
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Innovative therapeutic and 
preventative neurotechnologies
A subset of the above imaging methods have variations
capable of patterned neuronal stimulation, notably elec-
trical and optical methods. This may enable repair or
accommodation of disorders acquired during a lifetime
of trauma and environmental and immune factors. Some
psychiatric and neurodegenerative diseases can be pre-
vented at even earlier stages, via their inherited,
(auto)immune and microbial/viral origins. Genomics is
finally overcoming decades of false-positives in such dis-
eases including autism, schizophrenia, obsessive-compul-
sive disorder, bipolar disorder, etc. The reasons for the
improved discovery are larger cohorts and better geno-
typing via next-generation sequencing, for example for
de novo mutations in family trios including point muta-
tions and so-called structural variants. Imaging and mol-
ecular methods increasingly help classify and stratify
causes to enable preventative strategies ranging from
preconception carrier screening, lifestyle, immunogen/
allergen management, and small molecule/protein/gene
therapies to direct management of patterns of neuronal
activity. ❏
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